RxDoctor Payments Data

Cameron Turtle

Hematology & Oncology · Seattle, WANPI 1154599488

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $18,606 of the $21,370 with a category attached, or 87.1%. 6 manufacturers reported payments, led by AstraZeneca at 27.4% of the total.

$21,370in general payments, 2019–2025

Across 10 payments — averaging $2137.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$6K
  • Legend Biotech USA Inc.$6K
  • GSK$4K
  • Amgen$3K
  • Gilead$2K
  • Genentech, Inc.$500
$8,227,318in research payments, 2019–2025

Across 9 payments — averaging $914,146 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Bristol Myers Squibb$8.2M
  • Novartis$861

What the payments were for

  • Consulting fees$18,60687%
  • Speaking & faculty fees$5002%
  • Travel & lodging$2,26411%

General payments by program year

20
21
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca3$5,864
Legend Biotech USA Inc.2$5,611
GSK1$3,900
Amgen2$3,245
Gilead1$2,250
Genentech, Inc.1$500

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$21,370 in reported general payments places this provider in the 80th percentile of 349 hematology & oncology providers in Washington.

See all hematology & oncology providers in Washington

Other hematology & oncology in Seattle

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →